首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1733208

癲癇市場：依類型、治療方法、應用、最終用戶和地區，2026-2032年

Epilepsy Market By Type, Treatment, Application, End-Users, & Region for 2026-2032

出版日期: 2025年04月30日 | 出版商:

Verified Market Research | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄

2026-2032年癲癇市場評估

根據世界衛生組織估計，癲癇的盛行率呈上升趨勢，全球約有5,000萬人受其影響。此外，政府目的是加強精神健康保健和消除癲癇病恥感的支持措施營造有利於獲得治療和創新的氛圍。2024年將超過28.2億美元，2032年將達47.7億美元。

此外，引進新的診斷工具和治療方案等技術改進預計將改善患者的治療效果並鼓勵早期療育，從2026年到2032年的年複合成長率約為 7.52%。

癲癇病患病率的不斷上升會推動癲癇市場的發展嗎？

隨著各年齡層癲癇盛行率的增加，全球癲癇市場正迅速擴張。世界衛生組織（WHO）2024年3月的報告顯示，全球有超過6,500萬人患有癲癇，2022年至2023年期間新記錄病例增加了24%，令人擔憂。2024年2月，國際抗癲癇聯盟（ILAE）宣布，已開發國家的發生率為每年每10萬人61.4人，兒科患者數量增加了32%。根據2024年 1月的產業預測，全球癲癇藥物市場預計將在2023年達到 183億美元，到2028年的年複合成長率為 9.8%。

2024年2月，Pfizer公司的抗藥性癲癇基因療法獲得FDA加速核准，2024年3月，GlaxoSmithKline Plc的先進神經調節設備核准。2024年 1月，美國政府承諾透過美國國立衛生研究院投入 28億美元用於癲癇研究、開發和治療；2024年 4月，歐盟委員會啟動了一項 5億歐元的計劃，以改善成員國獲得癲癇治療的機會。

抗癲癇藥物的高價會抑制癲癇市場的成長嗎？

抗癲癇藥物（AED）的高價預計將阻礙癲癇市場的擴張，尤其是在中低收入國家。許多患者在接受這些重要藥物治療時面臨經濟挑戰，這可能導致違規和治療無效。根據癲癇基金會2024年1月發布的一項調查，美國近一半的癲癇患者難以負擔藥物費用，這對實現最佳治療效果構成了重大障礙。這種經濟負擔不僅影響患者的健康，還會導致與未治療的癲癇相關的醫療保健費用增加，例如急診就診和住院。

此外，較新的抗癲癇藥物和先進療法的費用通常過高，而且可能無法償付，這可能會進一步加劇這種情況。2024年 3月Health Affairs雜誌發表的一份報告發現，過去五年來 AED 的平均年成本上漲了 30%，引發了人們對治療可及性和公平性的擔憂。因此，患者和醫療保健系統持續的經濟負擔可能會阻礙市場擴張，並阻礙新的有效癲癇治療方法的開發和引進。解決這些成本障礙對於改善治療機會和刺激癲癇領域的發展非常重要。

The increasing prevalence of epilepsy, estimated by the World Health Organization to impact around 50 million people globally, fuels demand for improved therapies and management measures. Furthermore, supportive government measures targeted at enhancing mental health care and lowering the stigma associated with epilepsy are creating a more conducive atmosphere for treatment access and innovation. These variables, when combined, are driving significant growth in the epilepsy market.is surpassing USD 2.82 Billion in 2024 and reaching USD 4.77 Billion by 2032.

Furthermore, technological improvements, such as the introduction of novel diagnostic tools and treatment choices, improve patient outcomes and encourage early intervention is expected to grow at a CAGR of about 7.52% from 2026 to 2032.

Will Rising Prevalence of Epilepsy Disease Drive the Epilepsy Market?

The worldwide epilepsy market is rapidly expanding as the prevalence of epilepsy rises across all age groups. According to the World Health Organization's March 2024 report, over 65 million individuals worldwide suffer from epilepsy, with a troubling 24% increase in new cases documented between 2022 and 2023. In February 2024, International League against Epilepsy (ILAE) show that the incidence rate has climbed to 61.4 cases per 100,000 person-years in developed countries, with a 32% increase in pediatric cases. According to a January 2024 industry estimate, the global epilepsy therapeutics market would be worth USD 18.3 Billion in 2023, with a CAGR of 9.8% expected through 2028, owing mostly to improved diagnosis rates and novel treatment options.

In February 2024, Pfizer's gene therapy treatment for drug-resistant epilepsy was granted fast-track designation by the FDA, while GlaxoSmithKline's sophisticated neuromodulation device received regulatory approval in March 2024. In January 2024, the US government dedicated USD 2.8 Billion for epilepsy research and treatment development through the National Institutes of Health, while the European Commission started a €500 million project in April 2024 to increase epilepsy care access across member states.

Will High Cost of Antiepileptic Drugs Hinder the Growth of the Epilepsy Market?

The high cost of antiepileptic medications (AEDs) is expected to stymie the expansion of the epilepsy market, particularly in low- and middle-income nations. Many patients confront financial difficulties to receiving these critical medications, which can lead to noncompliance and ineffective therapy. According to an Epilepsy Foundation research published in January 2024, nearly half of people with epilepsy in the United States have difficulty purchasing their drugs, underlining a key hurdle in attaining optimal treatment outcomes. This financial burden not only has an influence on patient health, but it also leads to higher healthcare expenses associated with untreated epilepsy, such as emergency room visits and hospitalizations.

Furthermore, the cost of novel AEDs and advanced therapies might compound the situation, as these treatments are typically prohibitively expensive and may not be reimbursed by insurance. In March 2024, according to a report published in Health Affairs, the average annual cost of AEDs has risen by 30% in the last five years, raising concerns about treatment access and equity. As a result, the continuous financial burden on patients and healthcare systems may hinder market expansion, impeding the development and implementation of novel and effective epilepsy treatments. Addressing these cost barriers will be critical to enhancing access to care and driving growth in the epilepsy sector.

Category-Wise Acumens

Will Rising Demand for Idiopathic Drive the Epilepsy Market?

The increasing demand for idiopathic epilepsy treatments is expected to have a substantial impact on the epilepsy industry and its dominance. Pharmaceutical companies are increasing their R&D efforts as more patients seek effective treatments for this common type of epilepsy. For instance, in October 2023, UCB announced positive clinical trial findings for a novel medicine targeting idiopathic generalized epilepsy, demonstrating the industry's commitment to meeting this unmet need.

In September 2023, the U.S. FDA approved a new treatment specifically for idiopathic epilepsy, underscoring regulatory encouragement for innovation in this field. Moreover, in July 2023, the European Medicines Agency unveiled a strategic plan to boost research in neurological disorders, including epilepsy, indicating a growing focus on improving patient outcomes through better access to care and funding for research initiatives.

However, the symptomatic group is growing the quickest, owing to advances in diagnostic procedures and more knowledge of underlying illnesses that can cause seizures. The increased identification of symptomatic epilepsy, which is associated with structural or metabolic disorders, is encouraging more patients to seek treatment, expanding this segment's market position.

Will High Incidence of Generalized Seizures Fuel the Epilepsy Market?

The increasing prevalence of generalized seizures is likely to fuel expansion in the epilepsy market, emphasizing the need for improved treatments. Pharmaceutical companies are focusing more on creating tailored medicines as a large percentage of people suffer from generalized seizures. In October 2023 Eisai stated that a clinical trial for a novel medicine specifically intended for generalized tonic-clonic seizures had been successful, showing the industry's response to the growing demand for effective therapies.

In September 2023, the FDA authorized a novel version of an existing medicine for treating generalized seizures, demonstrating regulatory support for epilepsy care innovation. Furthermore, in July 2023, the World Health Organization highlighted the importance of addressing seizure disorders in its health initiatives, emphasizing the need for improved global access to epilepsy treatments, thereby increasing the focus on generalized seizure management in public health strategies.

Meanwhile, the focal seizures segment is expanding the fastest, driven by increased awareness and diagnosis of this type of epilepsy. With developments in treatment modalities and personalized approaches to care, more individuals with focal seizures are being diagnosed and managed, boosting growth in this market as healthcare practitioners focus more on tailored therapy for specific seizure types.

Country/Region-wise

Will Rising Investments in Research and Developments in North America Drive the Epilepsy Market?

Rising investment in research and development (R&D) in North America is expected to considerably impact the epilepsy market. According to a report from the National Institutes of Health (NIH), funding for neurological research, including epilepsy, will exceed USD 2 Billion by 2023, demonstrating the government's commitment to improving treatment choices. Companies such as UCB and Jazz Pharmaceuticals have also announced significant increases in their R&D budgets, with UCB intending to invest USD 1.5 Billion in innovative therapeutics over the next five years, with the goal of developing new antiepileptic drugs that address unmet patient requirements.

Furthermore, technological improvements and collaboration between pharmaceutical corporations and academic institutions have accelerated the rate of invention. In March 2024, the FDA authorized a new seizure monitoring gadget manufactured by Medtronic, demonstrating the expanding convergence of technology and epilepsy therapy. These investments not only help to create novel medicines, but also improve diagnostic tools and patient management procedures, all of which contribute to the dominance and efficacy of the North American epilepsy market.

Will Growing Awareness of Epilepsy Disorder in Asia Pacific Propel the Epilepsy Market?

The increasing awareness of epilepsy problems in Asia Pacific is predicted to greatly boost the epilepsy industry. Recent attempts by health organizations and governments to educate the public about epilepsy have resulted in a greater awareness of the condition and its implications. For instance, in February 2024, World Health Organization (WHO) report published found that approximately 75% of people with epilepsy in low- and middle-income nations go untreated, underscoring the critical need for awareness and care. This increased awareness encourages more people to seek diagnosis and treatment, which drives demand for antiepileptic medications and therapies.

Furthermore, regional governments are actively promoting programs to improve epilepsy treatment. In January 2024, the Indian government announced a national effort to improve mental health services, including specialized epilepsy care, with the goal of closing the country's treatment gap. Companies such as Sun Pharmaceutical have responded by focusing more on creating affordable epilepsy treatments for the Asian market. As awareness grows, both governmental and private funding are likely to flow into research, education, and the development of more effective therapies, boosting the region's growth in the epilepsy industry even further.

Competitive Landscape

The competitive landscape of the epilepsy market is characterized by a diverse array of companies ranging from large pharmaceutical firms to specialized biotech startups. This sector is marked by continuous innovation, with a focus on developing new antiepileptic drugs (AEDs), including novel mechanisms of action and formulations aimed at improving patient adherence and minimizing side effects. Additionally, the rise of digital therapeutics and wearable technology for seizure monitoring is reshaping the market dynamics, fostering partnerships between tech companies and healthcare providers. Regulatory approvals and clinical trial outcomes play critical roles in shaping competition, as companies strive to differentiate their products in a crowded marketplace while addressing unmet needs in epilepsy treatment.

Some of the prominent players operating in the epilepsy market include:

UCB S.A.

Abbott Laboratories

GlaxoSmithKline plc

Bausch Health Companies, Inc.

Sumitomo Pharma Co. Ltd

Lundbeck A/S

Sanofi

Viatris, Inc.

Novartis AG

Latest Developments

In July 2023, Neurelis introduced a new device for dispensing its nasal spray treatment for acute seizures, enhancing patient accessibility in emergency scenarios. This idea aims to improve immediate care for seizure occurrences.

In July 2023, The FDA approved a new medication for focal seizures, expanding the available medicines in the epilepsy market. This approval demonstrates regulatory support for innovation as well as the need of appropriate management options for varied seizure types.

1 INTRODUCTION OF GLOBAL EPILEPSY MARKET

1.1 Introduction of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL EPILEPSY MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL EPILEPSY MARKET, BY TYPE

5.1 Overview
5.2 Idiopathic
5.3 Symptomatic
5.4 Cryptogenic

6 GLOBAL EPILEPSY MARKET, BY TREATMENT

6.1 Overview
6.2 Antiepileptic Drugs
6.3 Surgery
6.4 Vagus Nerve Stimulation
6.5 Ketogenic Diet

7 GLOBAL EPILEPSY MARKET, BY APPLICATION

7.1 Overview
7.2 Generalized Seizures
7.3 Focal Seizures
7.4 Absence Seizures
7.5 Tonic-Clonic Seizures

8 GLOBAL EPILEPSY MARKET, BY END-USERS

8.1 Overview
8.2 Hospitals
8.3 Clinics
8.4 Ambulatory Surgical Centers
8.5 Homecare Settings

9 GLOBAL EPILEPSY MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East and Africa

10 GLOBAL EPILEPSY MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 UCB S.A.
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Abbott Laboratories
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 GlaxoSmithKline plc
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Bausch Health Companies Inc.
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 Sumitomo Pharma Co. Ltd
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 H. Lundbeck A/S
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 Sanofi
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Viatris Inc.
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 Novartis AG
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 Johnson & Johnson
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments